SPECIAL BULLETIN (Feb. 2018) - Generic Dispensing Rate Adjustments and Flovent HFA Inhaler Moved to Preferred Status on PDL

Flovent HFA Inhaler Moved to Preferred Status on the Preferred Drug List

Effective Feb. 3, 2017, Flovent HFA Inhaler has been moved to preferred status on the North Carolina Medicaid and NC Health Choice (NCHC) Preferred Drug List (PDL). This change is being made since Teva Pharmaceuticals has discontinued sales of QVAR Inhaler and to allow providers another preferred inhaled corticosteroid option.

Teva is replacing QVAR Inhaler with QVAR RediHaler, which is non-preferred. Patients and caregivers are encouraged to speak with a healthcare professional about how this transition may impact their current treatment plan.

Generic Dispensing Rate Adjustments

Generic dispensing rate adjustments go into effect on Feb. 1, 2018. These rates are based on the Generic Dispensing Rate Report for fourth quarter 2017.